Stafloxacin therapy against Mycoplasma genitalium infections

Sitafloxacin versus moxifloxacin-based sequential treatment for Mycoplasma genitalium infections, multi-center, open-label, randomized controlled trial. - SGMG

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031230111

Enrollment

112

Registered

2023-06-06

Start date

2023-08-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mycoplasma genitalium Urithritis, Proctitis, Sexually transmitted infections, Mycoplasma genitalium, Sitafloxacin, Moxifloxacin, Sequential therapy, ParC, GyrA

Interventions

Study group 1. Sitafloxacin 200mg daily for 7 days Control group 1. Doxycycline 200mg daily for 7 days followed by moxifloxacin 400mg daily for 7 days Administration of doxycycline for up to 7 days is

D016449

sitafloxacin, sequential therapy, moxifloxacin, doxycycline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients provided an informed consent in writing. 2. Patients aged 18 years or older. 3. Patients diagnosed with Mycoplasma genitalium by urine or rectal sample

Exclusion criteria

Exclusion criteria: 1. Individuals with pregnancy 2. Individuals with a history of known hypersensitivity to sitafloxacin, doxycycline or moxifloxacin. 3. Individuals who are judged by their physicians in charge to be ineligible for any reason

Design outcomes

Primary

Measure	Time frame
Cure rate	—

Secondary

Measure	Time frame
Changes of bacterial load after intervention New development of resistant associated mutations after intervention	—

Contacts

Public ContactAndo Naokatsu

National Center for Global Health and Medicine

ando.n@jihs.go.jp+81-3-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026